General Information of This Drug (ID: DMPQAGE)

Drug Name
Mycophenolate mofetil   DMPQAGE
Synonyms
mycophenolate mofetil; 128794-94-5; CellCept; 115007-34-6; RS 61443; RS-61443; Munoloc; Mycophenolic acid morpholinoethyl ester; TM-MMF; Mycophenylate mofetil; Mycophenolatemofetil; UNII-9242ECW6R0; HSDB 7436; Cellcept (TN); 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; CHEBI:8764; C23H31NO7; Mycophenolate mofetil (CellCept); 9242ECW6R0; 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate; Myfenax; RS-61443-190; CellCept; MMF; CellCept (TN); ME-MPA; MMF CellCept(TM); R-99; Mycophenolate mofetil (JAN/USAN); CellCept, RS 61443, TM-MMF, Mycophenolate mofetil; 2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; 2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate; 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate;4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
Therapeutic Class
Immunosuppressive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
14 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Testicular lymphoma DISC2M2N N.A. Approved [1]
Splenic marginal zone lymphoma DISCGTZY N.A. Approved [1]
Small intestine lymphoma DISDOS6S N.A. Approved [1]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified DIS5OHQF N.A. Approved [1]
MALT lymphoma DIS1AVVE N.A. Approved [1]
Hepatosplenic T-cell lymphoma DIS7KMY9 N.A. Approved [1]
Middle East Respiratory Syndrome (MERS) DIS5VPYU 1D64 Approved [2]
Myeloproliferative neoplasm DIS5KAPA 2A20 Approved [1]
Recurrent adult burkitt lymphoma DIS6V60A 2A85.6 Approved [1]
Large granular lymphocytic leukemia DISHOPPI 2A90.1 Approved [1]
Myeloid leukaemia DISMN944 2B33.1 Approved [1]
Systemic lupus erythematosus DISI1SZ7 4A40.0 Approved [1]
Interstitial cystitis DIS7CAJA GC00.3 Approved [1]
Organ transplant rejection DISDAKTM NE84 Approved [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 Indications(s)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pemphigus vulgaris DISENR62 EB40 Phase 3 [3]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Post-transplant lymphoproliferative disorder DISTS43D 2B32 Discontinued in Phase 3 [4]
------------------------------------------------------------------------------------
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Leukemia DISNAKFL N.A. Discontinued in Phase 2 [5]
------------------------------------------------------------------------------------
2 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Classic Hodgkin lymphoma DISV1LU6 N.A. Investigative [1]
Immune System disease DISPV68Z 4A01-4B41 Investigative [6]
------------------------------------------------------------------------------------

References

1 Mycophenolate mofetil FDA Label
2 High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses. J Virol. 2019 May 29;93(12). pii: e00023-19.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6831).
4 Efficacy of Ondansetron on Vomiting Due to Acute Gastroenteritis in Pediatric During Winter
5 Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).